Prana Biotechnolo receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alterity Therapeutics Ltd ADR (ATHE)
Alterity Therapeutics Ltd ADR stock price live, this page displays NASDAQ ATHE stock exchange data. View the ATHE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alterity Therapeutics Ltd ADR real time stock price chart below.
What Is the Alterity Therapeutics Ltd ADR Stock Price Today?
The Alterity Therapeutics Ltd ADR stock price today is 3.4900.
What Is the Stock Symbol for Alterity Therapeutics Ltd ADR?
The stock symbol for Alterity Therapeutics Ltd ADR is "ATHE."
What Stock Exchange Does Alterity Therapeutics Ltd ADR Trade On?
Alterity Therapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Alterity Therapeutics Ltd ADR a Good Stock to Buy?
Determining whether Alterity Therapeutics Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATHE quote. (ISIN: US02155X2053)
What Is the Alterity Therapeutics Ltd ADR Stock Price Today?
The Alterity Therapeutics Ltd ADR stock price today is 3.4900.
What Is the Stock Symbol for Alterity Therapeutics Ltd ADR?
The stock symbol for Alterity Therapeutics Ltd ADR is "ATHE."
What Stock Exchange Does Alterity Therapeutics Ltd ADR Trade On?
Alterity Therapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Alterity Therapeutics Ltd ADR a Good Stock to Buy?
Determining whether Alterity Therapeutics Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATHE quote. (ISIN: US02155X2053)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.3800
3.5700
52 wk Range
2.6600
5.8922
ATHE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.38003.5700
52 wk Range
2.66005.8922
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATHE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
13.2500
Upside
+279.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Prana Biotechnolo receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Prana Biotechnolo receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Prana Biotechnolo receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.2500
(+279.66% Upside)
Earnings
Latest Release
Aug 28, 2026
EPS / Forecast
-0.07 / --
Revenue / Forecast
806.59K / --
Compare ATHE to Peers and Sector
Metrics to compare | ATHE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATHEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.9x | −5.7x | −0.3x | |
PEG Ratio | 0.22 | 0.00 | 0.00 | |
Price/Book | 2.1x | 3.8x | 2.6x | |
Price / LTM Sales | 25.1x | 12.3x | 3.0x | |
Upside (Analyst Target) | 263.0% | 243.4% | 56.4% | |
Fair Value Upside | Unlock | −2.5% | 7.2% | Unlock |
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alterity Therapeutics ADR (ATHE) Stock Price Today?
The Alterity Therapeutics ADR stock price today is 3.4900 USD.
What Stock Exchange Does Alterity Therapeutics ADR Trade On?
Alterity Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Alterity Therapeutics ADR?
The stock symbol for Alterity Therapeutics ADR is "ATHE."
What Is the Alterity Therapeutics ADR Market Cap?
As of today, Alterity Therapeutics ADR market cap is 62.6800M USD.
What Is Alterity Therapeutics ADR's Earnings Per Share (TTM)?
The Alterity Therapeutics ADR EPS (TTM) is -0.1112.
From a Technical Analysis Perspective, Is ATHE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Alterity Therapeutics ADR Stock Split?
Alterity Therapeutics ADR has split 2 times.
How Many Employees Does Alterity Therapeutics ADR Have?
Alterity Therapeutics ADR has 11 employees.
What is the current trading status of Alterity Therapeutics ADR (ATHE)?
As of Oct 01, 2026, Alterity Therapeutics ADR (ATHE) is trading at a price of 3.4900 USD, with a previous close of 3.6500 USD. The stock has fluctuated within a day range of 3.3800 USD to 3.5700 USD, while its 52-week range spans from 2.6600 USD to 5.8922 USD.
What Is Alterity Therapeutics ADR (ATHE) Price Target According to Analysts?
The average 12-month price target for Alterity Therapeutics ADR is 13.2500 USD, with a high estimate of 16 USD and a low estimate of 10 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +279.66% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.